Core Viewpoint - COSCIENS Biopharma Inc. has received director nominations from Goodwood Fund and Puccetti Funds Management Inc. for its upcoming Annual and Special Meeting of Shareholders, indicating potential changes in governance and strategic direction [1][2]. Company Overview - COSCIENS Biopharma Inc. is a life sciences company focused on developing and commercializing a diverse range of cosmeceutical, nutraceutical, and pharmaceutical products, utilizing proprietary extraction technology from renewable plant resources [3]. - The company's product portfolio includes macimorelin (Macrilen®; Ghryvelin®), which is the first and only FDA and EMA approved oral test for diagnosing adult growth hormone deficiency [3]. Market Position - COSCIENS is publicly traded on both the NASDAQ Capital Market and the Toronto Stock Exchange under the ticker symbol "CSCI" [4].

Core Viewpoint - COSCIENS Biopharma Inc. has repositioned itself as a pure-play natural-based product company following a strategic review and pipeline prioritization, while continuing efforts to streamline operations and cut costs [1] Financial Overview - The company reported a consolidated net loss of $3.7 million, or $1.16 loss per common share, for the first quarter of 2025, compared to a net loss of $1.4 million, or $0.76 loss per common share, for the same period in 2024 [6] - Total revenue for the first quarter of 2025 was $1.5 million, down from $2.1 million in the same period in 2024, primarily due to a $0.7 million decrease in sales of Avenanthramides, Beta Glucan, and Oat Oil [7] - Operating expenses increased to $4.0 million from $2.7 million in the same period in 2024, mainly due to higher selling, general, and administrative costs following a merger [13] Cash Position - As of March 31, 2025, the company had $13.8 million in cash and cash equivalents [5] Clinical Development - The company is advancing its Phase 2 clinical trial for Avenanthramide tablets, having successfully completed Phase 1 with no significant adverse events observed [4] - The Phase 2a clinical efficacy study commenced on March 15, 2025, with the first cohort of 10 patients completing their treatment, and the Data and Safety Monitoring Board recommended continuation with a second cohort [4] Product Development - COSCIENS is working on a new portfolio of nutraceuticals, including an Oat Beta Glucan Chewable Bar for cholesterol reduction and a Yeast Beta Glucan Powder as an immune booster [4] - The company has completed the scale-up project for Pressurized Gas eXpanded Technology (PGX) at its Edmonton facility, ready to produce Yeast Beta Glucan at a small-scale commercial level [4]

Core Viewpoint - COSCIENS Biopharma Inc. has initiated its Phase 2a clinical efficacy study for its avenanthramides product, aimed at managing inflammation-related conditions, following a successful Phase 1 trial that demonstrated a favorable safety profile [1][4][5]. Group 1: Clinical Study Details - The Phase 1-2a clinical trial, named the AvenActive study, began in November 2023 and involved 72 healthy subjects, with no significant adverse events reported [3][8]. - The Phase 2a study will enroll 20 patients with mild to moderate inflammation, testing doses of 480 mg and 960 mg per day [4][5]. - Initial dosing for the Phase 2a study is expected to occur on March 14, 2025, at the Montreal Heart Institute [4][8]. Group 2: Product Information - Avenanthramides are di-phenolic compounds found in oats, known for their antioxidant and anti-inflammatory properties [2]. - The study will assess inflammatory biomarkers in blood, focusing on cytokines, chemokines, and high-sensitivity C-reactive protein [5]. Group 3: Company Strategy and Market Potential - The successful completion of the Phase 1 study is viewed as a critical milestone, positioning the company for potential out-licensing and commercialization opportunities [6]. - The company aims to become a global leader in natural-based health and wellness products, with avenanthramides seen as a transformative product [6][10].